To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders
Intervention: Lobeline (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Reese Jones, M.D., Principal Investigator, Affiliation: Langley Porter Psychiatric Institute
Summary
To assess the safety and tolerability of 7. 5, 15 and 30 mg of sublingual lobeline.
Clinical Details
Official title: Safety and Tolerability Study of Sublingual Lobeline
Study design: Primary Purpose: Diagnostic
Primary outcome: Safety
Detailed description:
The primary objective of this study is to characterize the pharmacokinetics of three
ascending doses of lobeline in normal volunteers.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy individuals with a body mass index between 18 and 30.
- Willing and able to give written consent.
- Must have a negative drug test
- Females must have a negative pregnancy test prior to study drug administration
- Must have no medical contraindications as determined by routine testing
Exclusion Criteria:
- Please contact the site for more information
Locations and Contacts
U of CA, San Francisco, San Francisco, California 94143, United States
Additional Information
Starting date: September 2004
Last updated: October 25, 2007
|
